Heart Failure Clinical Trial

A Study of CLR325 in Chronic Stable Heart Failure Patients.

Summary

The purpose of this study was to determine the safety and tolerability of CLR325 intravenous (i.v.) infusion in patients with stable heart failure to determine if further clinical development of the drug in this indication was warranted.

View Eligibility Criteria

Eligibility Criteria

Key Inclusion Criteria:

Male and female patients >18 years of age
Body weight between 50 kg and 140 kg
Cardiac ejection fraction of ≤ 45% assessed within the last 6 months
For PA catheter cohorts, patients who are planned to have a clinically indicated pulmonary artery catheter in place prior to randomization
In the opinion of the investigator, heart failure patients who do not require a change in their dose of acetylcholinesterase (ACE), angiotensin receptor blocker (ARB), β-blocker, mineralocorticoid receptor antagonist, or diuretic for 24 h after randomization.
At Baseline, vital signs (systolic and diastolic blood pressure and pulse rate) assessment in the supine position after the subject has rested for at least five minutes.

Key Exclusion Criteria:

Impaired renal function as indicated by clinically significant abnormal creatinine values (Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2 calculated using the Modification of Diet in Renal Disease Study (MDRD) equation)
History of chronic hepatitis of any non-cardiac etiology
History of any active or clinically significant cardiac tachyarrhythmia (such as recurrent atrial fibrillation with rapid ventricular response within the last year) and patients with chronic atrial fibrillation with a pulse rate ≤ 100 bpm
Patients who received an i.v. infusion of a cardiac inotrope (e.g., dobutamine or milrinone) in the last 24 h prior to randomization
Patients with any significant change in their dose of their ACE, ARB, mineralocorticoid receptor antagonist, diuretic, or β-blocker within the last 12 h

Patients with known significant valvular heart diseases indicated by the following:

severe aortic stenosis (aortic valve area < 1.0 cm2 or peak gradient > 50 mm Hg as determined by echocardiography)
severe mitral stenosis
History of acute coronary syndrome within the last 60 days as determined by both clinical and enzymatic criteria
For echocardiography-based cohorts only, patients admitted to an inpatient setting for acute decompensated heart failure within the last 30 days
For PA catheter cohorts, patients with a pulmonary capillary wedge pressure of <10 mm Hg at Baseline. For echocardiographic cohorts, patients with a lateral E/E' ratio of < 7 on their baseline echocardiogram. For patients in whom a lateral E/E' ratio cannot be determined (e.g., patients in atrial fibrillation), a central venous pressure of < 5 mm Hg on baseline echocardiogram as determined by inferior vena cava criteria.

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

26

Study ID:

NCT02696967

Recruitment Status:

Completed

Sponsor:

Novartis Pharmaceuticals

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 11 Locations for this study

See Locations Near You

Novartis Investigative Site
Chicago Illinois, 60611, United States
Novartis Investigative Site
Saint Louis Missouri, 63110, United States
Novartis Investigative Site
Cleveland Ohio, 44195, United States
Novartis Investigative Site
Philadelphia Pennsylvania, 19104, United States
Novartis Investigative Site
Houston Texas, 77030, United States
Novartis Investigative Site
Tacoma Washington, 98405, United States
Novartis Investigative Site
Aalst , 9300, Belgium
Novartis Investigative Site
Regensburg Bavaria, 93053, Germany
Novartis Investigative Site
Greifswald , 17475, Germany
Novartis Investigative Site
Amsterdam , 1081 , Netherlands
Novartis Investigative Site
Singapore , 16960, Singapore

How clear is this clinincal trial information?

Study is for people with:

Heart Failure

Phase:

Phase 2

Estimated Enrollment:

26

Study ID:

NCT02696967

Recruitment Status:

Completed

Sponsor:


Novartis Pharmaceuticals

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider